SOURCE: Althea Technologies, Inc.

August 22, 2006 06:00 ET

Althea Technologies to Manufacture Altus Pharmaceutical's ALTU-238 Human Growth Hormone for Phase III Studies

SAN DIEGO, CA -- (MARKET WIRE) -- August 22, 2006 -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that it has been awarded a contract from Altus Pharmaceuticals Inc. to produce its ALTU-238 product candidate, a crystallized formulation of Human Growth Hormone (HGH) that is designed to be administered once-weekly through a fine gauge needle for the treatment of HGH disorders. Altus Pharmaceuticals Inc. (NASDAQ: ALTU), based in Cambridge, MA, is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders.

"Althea Technologies is a seasoned CMO with significant experience in the manufacture of recombinant proteins," commented Sheldon Berkle, President and CEO of Altus. "We look forward to working together through technology transfer and the installation and qualification of the key equipment necessary for the production of ALTU-238. We feel confident in their ability to manufacture reliable quantities of ALTU-238 for our planned Phase III clinical trials that meet our high standards of quality and patient safety."

Althea Technologies will manufacture the Phase III clinical trial material of ALTU-238 human growth hormone in its newly expanded cGMP manufacturing facilities at the company's San Diego, California campus.

President and Co-CEO of Althea, Dr. Magda Marquet, added, "We are pleased that Altus Pharmaceuticals selected Althea Technologies to manufacture their innovative ALTU-238 product. As a leader in providing highly technical drug development services to the industry, we are committed to working with Altus to effectively and efficiently manufacture ALTU-238."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing and development services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, aseptic filling, and gene quantification using real-time PCR and gene expression analysis under GLP conditions. Additionally, Althea has introduced new services and technologies for the identification and understanding of gene signatures with innovative tools such as the company's proprietary eXpress Profiling(™) (XP-PCR) technology. For more information, visit www.altheatech.com.

About Altus Pharmaceuticals Inc.

Altus Pharmaceuticals, headquartered in Cambridge, MA is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com.

Contact Information

  • Contact:

    Althea Technologies, Inc.
    Alan Moore
    Executive Vice President and CBO
    (858) 882-0205
    Email Contact